In a significant move to reshape the landscape of pediatric mental health, Firefly Neuroscience and NeuroSigma have announced a strategic partnership that bridges the gap between AI-driven diagnostic precision and non-pharmaceutical intervention. By integrating Firefly’s FDA-cleared Evoke brain-mapping platform with NeuroSigma’s Monarch eTNS System, the two companies aim to address the persistent challenges in diagnosing and treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children.
This collaboration marks a pivotal shift toward "precision neuroscience," moving the industry away from subjective behavioral assessments toward a future defined by objective, data-driven clinical decision-making.
The Core Partnership: Bridging Diagnostics and Treatment
The partnership is built on a clear objective: to provide clinicians with both the "eyes" to see how a child’s brain is functioning and the "tools" to treat the condition without relying on traditional pharmacotherapy.
Firefly Neuroscience, an AI-focused firm, has developed the Evoke platform, which utilizes quantitative electroencephalography (qEEG) and event-related potential (ERP) testing. When a clinician uses Evoke, they are essentially creating a digital map of a patient’s brain function, supported by a proprietary database of over 200,000 scans.
NeuroSigma brings to the table the Monarch eTNS (external Trigeminal Nerve Stimulation) System. As the first FDA-cleared non-drug treatment for pediatric ADHD, the device uses a small, adhesive patch worn on the forehead during sleep to deliver mild electrical pulses to the trigeminal nerve. By combining these two technologies, the partnership creates a closed-loop system where clinicians can diagnose, prescribe, and monitor treatment efficacy through objective biological markers rather than qualitative reports alone.
Chronology of Development: A Path to Market
The road to this partnership is defined by years of clinical validation and strategic growth for both firms:
- 2019/2020s: NeuroSigma secures FDA clearance for the Monarch eTNS System, establishing a new category of "digital therapeutics" for ADHD.
- March 2026: Firefly Neuroscience announces a breakthrough in identifying EEG/ERP biomarkers capable of distinguishing between the three primary ADHD presentations: inattentive, hyperactive-impulsive, and combined.
- July 2026: NeuroSigma officially launches the second-generation Monarch device, experiencing immediate demand with a waitlist exceeding 1,500 patients.
- September 2026: Recognizing the economic barriers to healthcare, NeuroSigma introduces third-party installment plans to broaden access to the Monarch device.
- Late 2026 (Current): Firefly and NeuroSigma announce their formal partnership, with Firefly facilitating the introduction of Monarch into its established network of psychiatry and neurology practices.
Supporting Data: Why Objective Measurement Matters
The primary frustration for parents and clinicians in ADHD care has long been the reliance on behavioral rating scales, which can be prone to bias or misinterpretation. Firefly’s Evoke platform addresses this by quantifying brain activity.
The company’s research into EEG/ERP biomarkers is the "scientific backbone" of this partnership. By identifying specific patterns associated with the three ADHD subtypes, Firefly provides a roadmap for treatment. If a child’s brain scan shows a specific pattern of inattention, clinicians can now leverage this data to justify the use of the Monarch device, rather than defaulting to stimulants or other medications.
Furthermore, the scale of Firefly’s database—comprising 200,000+ brain scans—allows for machine learning models to continuously improve. As the platform is used more frequently, the "normative" brain patterns become clearer, leading to even greater accuracy in identifying pediatric neurodevelopmental anomalies.
Official Responses: Leaders on the Future of Neuroscience
The leadership teams of both organizations emphasize that this deal is not merely a distribution agreement, but a fundamental change in clinical philosophy.
Greg Lipschitz, CEO of Firefly Neuroscience, stated:
"This partnership represents an important step toward a more objective and personalized approach to pediatric ADHD care. Clinicians need better tools to understand how an individual patient’s brain is functioning, more treatment options from which to choose, and objective ways to evaluate changes over time. By introducing NeuroSigma’s FDA-cleared, non-drug therapy to our Evoke clinician network, we are connecting measurement-driven practices with an important treatment option for eligible children and their families."
Colin Kealey, President and CEO of NeuroSigma, added:
"Firefly has built a network of clinicians who are already embracing a more objective, measurement-driven approach to brain health. These clinics are well-positioned to evaluate innovative treatment options for children and families seeking an alternative to medication. With our second-generation Monarch device now shipping and expanded payment options available, this partnership gives us an efficient pathway to educate more clinicians and broaden access to the first FDA-cleared, non-drug treatment for pediatric ADHD."
Broader Implications: The "Precision" Healthcare Revolution
1. Reducing the Stigma and Side Effects of Medication
For many families, the prospect of starting a child on stimulants is daunting due to potential side effects, including sleep disruption, appetite loss, and personality changes. The Monarch device offers a non-pharmacological alternative that operates while the child sleeps. This partnership effectively places this tool into the hands of the practitioners most likely to be consulted by concerned parents.
2. The Rise of "Diagnostic Workflows"
Firefly is not stopping with NeuroSigma. The company recently announced a collaboration with Radial, an organization operating a network of brain medicine clinics. By integrating Evoke with Radial’s "RadialOS" (an AI-native operating system), Firefly is creating a comprehensive diagnostic ecosystem. This implies that in the near future, a visit to a psychiatrist for suspected ADHD will look very different: it will involve a brain-mapping session that produces a quantifiable report, followed by a treatment plan tailored to those specific findings.
3. Future Expansion into Other Neurodevelopmental Conditions
While the current focus is on pediatric ADHD, the implications are much wider. NeuroSigma is already investigating the Monarch device for:
- Autism Spectrum Disorder (ASD)
- Drug-resistant epilepsy
- Learning disabilities
The FDA has already granted the Monarch device "Breakthrough Device Designation" for drug-resistant epilepsy, signaling that the regulatory body sees significant potential in trigeminal nerve stimulation. Should these trials prove successful, the partnership between Firefly and NeuroSigma could become the industry standard for managing a vast array of neurological and neurodevelopmental conditions.
Conclusion: A New Standard for Care
The collaboration between Firefly Neuroscience and NeuroSigma arrives at a critical juncture in the history of mental healthcare. As the prevalence of pediatric ADHD continues to rise, the limitations of traditional, symptomatic-based diagnostic methods have become increasingly apparent.
By marrying high-fidelity, AI-driven brain-mapping with non-invasive, neuro-modulatory treatment, this partnership is doing more than just selling products—it is advocating for a shift in the standard of care. For the thousands of families navigating the difficult path of ADHD diagnosis and treatment, this integration offers something that has been in short supply: objective data, personalized options, and a clearer pathway to improvement. As the technology continues to evolve and the clinical data accumulates, this model of "measurement-driven" brain health is poised to become the cornerstone of 21st-century pediatrics.
About the Author
